Heparin Binding Protein as a Prognostic Biomarker of Sepsis Severity

Heparin Binding Protein as a Reliable Prognostic Biomarker for Severity of Sepsis in the Intensive Care Unit

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05610020

Enrollment

Registered

2022-11-08

Start date

2021-10-01

Completion date

2022-10-01

Last updated

2022-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBP, Sepsis

Brief summary

the aim of the study is to correlate between the severity of sepsis and serum heparin binding protein in the patients admitted to ICU with sepsis., and detect its value as a prognostic biomarker in sepsis

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* adult whose age between 20 to70 years old * patients suffered from sepsis or septic shock (under the third international consensus definition of sepsis and septic shock)

Exclusion criteria

* Any pregnancy female * Any patient who is Neutropenic secondary to malignancy * Patients who is taking immunosuppressive therapy * Patients who is suffering fromHematological malignancy

Design outcomes

Primary

Measure	Time frame	Description
Evaluate the level of Heparin binding protein in relation to patient clinical improvement measured by SOFA Score	72 hours after meeting sepsis ceriteria	Correlates the change of the level of Heparin binding protein in ng/ml to the clinical improvement of the patients which is measured by SOFA score

Secondary

Measure	Time frame	Description
Heparin binding protein and mortality	28 days after meeting sepsis ceriteria	Correlates the change of the level of Heparin binding protein in ng/ml And how can it is used to predict mortality

Countries

Egypt

Outcome results